Drugs / CA102N
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03616574 | Apr 2019 → Feb 2022 | colorectal cancer | Holy Stone Healthcare Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06039202 | Dec 2027 → Oct 2030 | colorectal cancer | Holy Stone Healthcare Co., Ltd | Suspended | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT05274204 | — | colorectal cancer | Holy Stone Healthcare Co., Ltd | No longer available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CA102N | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06039202 ↗ |
| Modality | Other / unclassified | “CA102N is a covalently bound conjugate of modified nimesulide (Nim) and NaHA, the sodium salt of hyaluronic acid (HA).” PMID 36331676 ↗ Nov 2022 |
| Route | Intravenous | “Administration sequence will be CA102N then TAS-102 (IV then oral)” NCT06039202 ↗ |